Literature DB >> 22314087

Effects of maternally-derived antibodies on serologic responses to vaccination in kittens.

Brian A Digangi1, Julie K Levy, Brenda Griffin, Michael J Reese, Patricia A Dingman, Sylvia J Tucker, Edward J Dubovi.   

Abstract

The optimal vaccination protocol to induce immunity in kittens with maternal antibodies is unknown. The objective of this study was to determine the effects of maternally-derived antibody (MDA) on serologic responses to vaccination in kittens. Vaccination with a modified live virus (MLV) product was more effective than an inactivated (IA) product at inducing protective antibody titers (PAT) against feline panleukopenia virus (FPV). IA vaccination against feline herpesvirus-1 (FHV) and feline calicivirus (FCV) was more effective in the presence of low MDA than high MDA. Among kittens with low MDA, MLV vaccination against FCV was more effective than IA vaccination. A total of 15%, 44% and 4% of kittens had insufficient titers against FPV, FHV and FCV, respectively, at 17 weeks of age. Serologic response to vaccination of kittens varies based on vaccination type and MDA level. In most situations, MLV vaccination should be utilized and protocols continued beyond 14 weeks of age to optimize response by all kittens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314087     DOI: 10.1177/1098612X11432239

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  9 in total

1.  WSAVA Guidelines for the vaccination of dogs and cats.

Authors:  M J Day; M C Horzinek; R D Schultz; R A Squires
Journal:  J Small Anim Pract       Date:  2016-01       Impact factor: 1.522

2.  Vaccination against Feline Panleukopenia: implications from a field study in kittens.

Authors:  Verena Jakel; Klaus Cussler; Kay M Hanschmann; Uwe Truyen; Matthias König; Elisabeth Kamphuis; Karin Duchow
Journal:  BMC Vet Res       Date:  2012-05-21       Impact factor: 2.741

Review 3.  Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.

Authors:  Stefan Niewiesk
Journal:  Front Immunol       Date:  2014-09-16       Impact factor: 7.561

4.  Feline Panleukopenia Outbreaks and Risk Factors in Cats in Animal Shelters.

Authors:  Teresa Rehme; Katrin Hartmann; Uwe Truyen; Yury Zablotski; Michèle Bergmann
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

5.  Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group.

Authors:  M J Day; C Crawford; M Marcondes; R A Squires
Journal:  J Small Anim Pract       Date:  2020-03-30       Impact factor: 1.522

6.  Diagnostic testing for feline panleukopenia in a shelter setting: a prospective, observational study.

Authors:  Linda S Jacobson; Kyrsten J Janke; Jolene Giacinti; J Scott Weese
Journal:  J Feline Med Surg       Date:  2021-04-13       Impact factor: 2.015

7.  Modified-Live Feline Calicivirus Vaccination Elicits Cellular Immunity against a Current Feline Calicivirus Field Strain in an Experimental Feline Challenge Study.

Authors:  Andrea M Spiri; Marilisa Novacco; Marina L Meli; Martina Stirn; Barbara Riond; Jonathan E Fogle; Felicitas S Boretti; Imogen Herbert; Margaret J Hosie; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2021-08-31       Impact factor: 5.048

8.  Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV).

Authors:  Mark Westman; Dennis Yang; Jennifer Green; Jacqueline Norris; Richard Malik; Yasmin A Parr; Mike McDonald; Margaret J Hosie; Sue VandeWoude; Craig Miller
Journal:  Viruses       Date:  2021-03-12       Impact factor: 5.048

9.  Fecal viral DNA shedding following clinical panleukopenia virus infection in shelter kittens: a prospective, observational study.

Authors:  Kyrsten J Janke; Linda S Jacobson; Jolene A Giacinti; J Scott Weese
Journal:  J Feline Med Surg       Date:  2021-06-25       Impact factor: 2.015

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.